Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Vertex Pharmaceuticals    VRTX

 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
10/11/2017 10/12/2017 10/13/2017 10/16/2017 10/17/2017 Date
154.02(c) 153.98(c) 152.91(c) 154.7(c) 155.05(c) Last
1 757 612 1 535 039 930 281 2 328 423 792 384 Volume
-0.32% -0.03% -0.69% +1.17% +0.23% Change
More quotes
Financials ($)
Sales 2017 2 297 M
EBIT 2017 487 M
Net income 2017 203 M
Finance 2017 642 M
Yield 2017 -
Sales 2018 2 686 M
EBIT 2018 840 M
Net income 2018 532 M
Finance 2018 1 740 M
Yield 2018 -
P/E ratio 2017 213,85
P/E ratio 2018 90,77
EV / Sales2017 16,7x
EV / Sales2018 13,9x
Capitalization 39 003 M
More Financials
Company
Vertex Pharmaceuticals, Inc. engages in the business of discovering, developing, manufacturing and commercializing small molecule drugs for patients with serious diseases.It focuses on development and commercializing therapies for the treatment of cystic fibrosis; infectious diseases, including... 
More about the company
Surperformance© ratings of Vertex Pharmaceuticals
Trading Rating : Investor Rating :
More Ratings
Latest news on VERTEX PHARMACEUTICALS
12:16p VERTEX PHARMACEUTICALS : Announces 10-Year, $500 Million Corporate Giving Commit..
10/16 VERTEX PHARMACEUTICALS : to Announce Third Quarter 2017 Financial Results on Oct..
10/16 NASDAQ 100 MOVERS : Jbht, wynn
10/12 VERTEX PHARMACEUTICALS : Report Summarizes Drug Metabolism and Disposition Study..
10/05 VERTEX PHARMACEUTICALS : New Tuberculosis Study Findings Have Been Reported by I..
10/01 VERTEX PHARMACEUTICALS : Provo girl finds a caring 'team of sisters' in BYU soft..
09/28 VERTEX PHARMACEUTICALS : to Present at the Leerink Partners Roundtable Series on..
09/28 VERTEX PHARMACEUTICALS : Announces Upcoming Presentations of Data at 2017 North ..
09/25 VERTEX PHARMACEUTICALS : to Present at the Leerink Partners Roundtable Series on..
09/21 VERTEX PHARMACEUTICALS : to Present at the Leerink Partners Roundtable Series on..
More news
Sector news : Bio Therapeutic Drugs
06:58p Regeneron-Sanofi drug succeeds mid-stage study
06:39pDJJOHNSON & JOHNSON : Outlook Buoyed by Drug Unit -- Update
06:48aDJJOHNSON & JOHNSON : Raises Guidance on Earnings Beat
10/05DJAppeals Court Rules Against Amgen in Patent Case -- Update
10/05DJAppeals Court Rules Against Amgen in Patent Case
More sector news : Bio Therapeutic Drugs
Latest Tweets
01:30pVertex Pharmaceuticals is taking a big step toward bolstering its standing in..
1
12:16p$VRTX Announces 10-Year, $500 Million Corporate Giving Commitment
4
12:16pVertex Pharmaceuticals : Announces 10-Year, $500 Million Corporate Giving Com.. 
11:14aVertex Pharmaceuticals Incorporated $VRTX EVP Michael Parini Sells 2,125 Shar.. 
07:32aBoston-based Vertex Pharmaceuticals has pledged $500 million to charitable ef..
4
More tweets
Qtime:540
News from SeekingAlpha
11:28a YOUR DAILY PHARMA SCOOP : Everybody's Gilead Problem, Halozyme's Further Progres..
10/10 VERTEX PHARMACEUTICALS : Excellence In Cystic Fibrosis, Strong Potential Ahead
10/06 YOUR DAILY PHARMA SCOOP : Gilead, Some History; Biogen's Spinraza, MDCO New Data..
10/02 YOUR DAILY PHARMA SCOOP : Alexion's Canada Pricing, Zogenix, RedHill, Flexion
09/29 Premarket analyst action - healthcare
Chart VERTEX PHARMACEUTICALS
Duration : Period :
Vertex Pharmaceuticals Technical Analysis Chart | VRTX | US92532F1003 | 4-Traders
Technical analysis trends VERTEX PHARMACEUTICALS
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
 
Mean consensus OUTPERFORM
Number of Analysts 27
Average target price 179 $
Spread / Average Target 16%
EPS Revisions
Managers
NameTitle
Jeffrey M. Leiden Chairman, President & Chief Executive Officer
Ian F. Smith Chief Operating Officer & Executive Vice President
Thomas Graney Chief Financial Officer & Senior Vice President
Jeffrey A. Chodakewitz Chief Medical Officer & Executive Vice President
David Matthew Altshuler Chief Scientific Officer & EVP-Global Research
Sector and Competitors
1st jan.Capitalization (M$)
VERTEX PHARMACEUTICALS107.56%39 003
GILEAD SCIENCES11.65%104 409
REGENERON PHARMACEUTICALS20.67%47 756
ACTELION23.24%29 757
GENMAB22.08%13 881
EXELIXIS, INC.66.06%8 529